Table 1.
Characteristics of included studies.
| Sl.No | Author | Year | Country | Study design | Total patients | Treatment group | Type of PRP | Control group | Mean Age (years) | SD | Male | Female | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Behera et al. | 2015 | India | RCT | 25 | 15 | LP-PRP | 10 | 38 | 7 | 6 | 19 | 1 year |
| 2 | Creaney et al. | 2011 | UK | RCT | 150 | 80 | LR-PRP | 70 | 49 | 8 | 85 | 65 | 6 mon |
| 3 | Gautam et al. | 2015 | India | RCT | 30 | 15 | LP-PRP | 15 | ND | ND | ND | ND | 6 mo |
| 4 | Gosens et al. | 2011 | Netherlands | RCT | 100 | 51 | LR-PRP | 49 | 47 | 8.5 | 48 | 52 | 2 yrs |
| 5 | Gupta et al. | 2019 | India | RCT | 80 | 40 | LR-PRP | 40 | 40.8 | ND | 34 | 46 | 1 year |
| 6 | Khaliq et al. | 2015 | Pakistan | RCT | 102 | 51 | LR-PRP | 51 | 34 | 10 | 57 | 45 | 3 weeks |
| 7 | Krogh et al. | 2013 | Denmark | RCT | 40 | 20 | LR-PRP | 20 | 45 | 7.3 | 18 | 22 | 3 mo |
| 8 | Lebiedzinski et al. | 2015 | Poland | RCT | 99 | 53 | LP-PRP | 46 | 47 | 10 | 40 | 59 | 1 year |
| 9 | Lim et al. | 2018 | South Korea | RCT | 105 | 61 | LR-PRP | 59 | 50.1 | 9.41 | 61 | 65 | 24 weeks |
| 10 | Linnanmaki et al. | 2020 | Finland | RCT | 79 | 40 | LP-PRP | 39 | 46 | 6 | 35 | 44 | 52 weeks |
| 11 | Martin et al. | 2019 | Spain | RCT | 71 | 36 | LP-PRP | 35 | 48.26 | 7.64 | 33 | 38 | 1 year |
| 12 | Merolla et al. | 2017 | Italy | RCT | 101 | 50 | LR-PRP | 51 | 47 | 7.06 | 56 | 45 | 2 yrs |
| 13 | Mishra et al. | 2013 | USA | RCT | 230 | 116 | LR-PRP | 114 | 47.4 | 6 | ND | ND | 24 weeks |
| 14 | Montalvan et al. | 2016 | France | RCT | 50 | 25 | LP-PRP | 25 | 46 | 7.8 | 34 | 16 | 12 mo |
| 15 | Palacio et al. | 2015 | Brazil | RCT | 40 | 20 | LP-PRP | 20 | 47.9 | ND | ND | ND | 180 days |
| 16 | Peerbooms et al. | 2010 | Netherlands | RCT | 100 | 51 | LR-PRP | 49 | 47 | 7.6 | 48 | 52 | 1 yr |
| 17 | Raeissadat et al. | 2014 | Iran | RCT | 40 | 20 | LR-PRP | 20 | 46.25 | 7.5 | 8 | 32 | 14.5 mo |
| 18 | Schoff et al. | 2017 | Germany | RCT | 36 | 18 | LP-PRP | 18 | 52.6 | 11.4 | 18 | 18 | 6 mo |
| 19 | Seetharamiaiah et al. | 2017 | India | RCT | 60 | 30 | LR-PRP | 30 | ND | ND | ND | ND | 6 mo |
| 20 | Tetschke et al. | 2015 | Germany | RCT | 53 | 33 | LR-PRP | 19 | 52 | 12.6 | 22 | 31 | 1 yr |
| 21 | Thanas et al. | 2011 | Greece | RCT | 28 | 14 | LR-PRP | 14 | 36.6 | 8 | 20 | 6 mo | |
| 22 | Tonk et al. | 2014 | India | RCT | 81 | 39 | LR-PRP | 42 | 41.15 | 30 | 51 | 1 year | |
| 23 | Varshney et al. | 2016 | India | RCT | 83 | 33 | LR-PRP | 50 | 46 | ND | 45 | 38 | 6 mo |
| 24 | Watts et al. | 2018 | UK | RCT | 81 | 40 | LR-PRP | 41 | 47 | 4 | 47 | 34 | 52 weeks |
| 25 | Yadav et al. | 2015 | India | RCT | 60 | 30 | LR-PRP | 30 | 37 | ND | 17 | 43 | 3 mo |
| 26 | Yerlikaya et al. | 2018 | Turkey | RCT | 90 | 60 | LR-PRP | 30 | 45 | 8.9 | 26 | 64 | 2 mo |
LP-PRP – Leucocyte Poor Platelet Rich Plasma; LR-PRP – Leucocyte Rich Platelet Rich Plasma; NA – Not Available; RCT – Randomized Controlled Trial; SD – Standard Deviation; UK – United Kingdom; USA – United States of America.